Status
Conditions
Treatments
About
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Full description
IRIS-CKD Screening Program: will focus on CKD screening in T2D. We will identify patients with T2D that have not received appropriate screening for CKD within the last 15 months and randomize patients to receive either a home kit to complete CKD screening ("home kit") versus a standard laboratory order ("laboratory order"). The primary objective is to evaluate whether delivery of home testing kits versus standard laboratory testing influences the degree to which patients receive guideline-recommended CKD screening. Patients will complete approximately 3 months of follow-up.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Screening Program-
Inclusion Criteria:
Exclusion Criteria:
• Chronic kidney disease (CKD) diagnosis
Primary purpose
Allocation
Interventional model
Masking
800 participants in 2 patient groups
Loading...
Central trial contact
Gretchen Sanders, MSN; Monica Leyva, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal